Background Hand eczema is a common inflammatory dermatosis that causes significant patient morbidity. Previous studies comparing psoralen-ultraviolet A (PUVA) with narrowband ultraviolet B (NB-UVB) have been small, nonrandomized and retrospective. Objectives To conduct an observer-blinded randomized controlled pilot study using validated scoring criteria to compare immersion PUVA with NB-UVB for the treatment of chronic hand eczema unresponsive to topical steroids. Methods Sixty patients with hand eczema unresponsive to clobetasol propionate 0Á05% were randomized to receive either immersion PUVA or NB-UVB twice weekly for 12 weeks with assessments at intervals of 4 weeks. The primary outcome measure was the proportion of patients achieving 'clear' or 'almost clear' Physician's Global Assessment (PGA) response at 12 weeks. Secondary outcome measures included assessment of the modified Total Lesion and Symptom Score (mTLSS) and the Dermatology Life Quality index (DLQI). Results In both treatment arms, 23 patients completed the 12-week assessment for the primary outcome measure. In the PUVA group, five patients achieved 'clear' and eight 'almost clear' [intention-to-treat (ITT) response rate 43%]. In the NB-UVB group, two achieved 'clear' and five 'almost clear' (ITT response rate 23%). For the secondary outcomes, median mTLSS scores were similar between groups at baseline (PUVA 9Á5, NB-UVB 9) and at 12 weeks (PUVA 3, NB-UVB 4). Changes in DLQI were similar, with improvements in both groups. Conclusions In this randomized pilot trial recruitment was challenging. After randomization, there were acceptable levels of compliance and safety in each treatment schedule, but lower levels of retention. Using validated scoring systems -PGA, mTLSS and DLQI -as measures of treatment response, the trial demonstrated that both PUVA and NB-UVB reduced the severity of chronic palmar hand eczema.
What does this study add?
• This pilot study suggests that both immersion PUVA and NB-UVB are effective treatments for palmar hand eczema.
• NB-UVB appears more likely to cause mild side-effects such as erythema.
• NB-UVB for hand eczema is a safe and reasonable alternative to PUVA.
• Recruitment of sufficient numbers of patients to a noninferiority study comparing PUVA with NB-UVB may be challenging.
Hand eczema (HE) is a common, relapsing inflammatory dermatosis characterized clinically by erythema, scaling, fissures, swelling and vesiculation. 1 It is a condition that causes significant patient morbidity, with symptoms such as pain, itch and burning contributing to insomnia, disruption of activities of daily living and work absenteeism. 2 The Scandinavian TOACS study estimated an incidence of 8Á8 per 1000 persons per year, with a history of atopic dermatitis being the most significant risk factor. 3 Meding and Jarvholm reported that up to 21% of patients take at least one period of absence of at least 7 days from work, and that 8% of patients will change their occupation due to HE severity. 4 HE classification can be based on aetiology or morphology, with common subtypes including atopic, irritant contact, allergic contact, pompholyx, hyperkeratotic and mixed. Following failure of topical treatment, systemic therapy or phototherapy is often needed. Phototherapy has several advantages over oral systemic treatment: no blood monitoring is required, and side-effects associated with retinoids or immunosuppressant medication can be avoided. Disadvantages include equipment set-up and staffing costs, multiple patient hospital visits, risk of skin erythema and burning, and the potential to induce photodamage and cutaneous malignancy.
Following the introduction of psoralen-ultraviolet A (PUVA) for psoriasis, the use of PUVA for HE emerged in the 1980s without any large-scale clinical trials. The efficacy of narrowband ultraviolet B (NB-UVB) for generalized atopic eczema has been demonstrated in randomized controlled trials. 5 The use of NB-UVB for HE has been advocated by some dermatologists but is not widespread. Studies comparing PUVA with NB-UVB for HE have been small, nonrandomized and retrospective, and have often included other noneczematous dermatoses. More importantly, standardized skin severity scoring systems were not used. [6] [7] [8] [9] Perhaps due to concerns that hand NB-UVB may not penetrate palmar skin and possible problems with erythema, PUVA has remained the phototherapy treatment of choice for HE. We identified the need for a formal comparison of NB-UVB with PUVA for HE in a prospective, randomized setting using validated scores. NB-UVB has potential logistical advantages, including cheaper costs and faster patient turnaround time (no hand soaking required and shorter irradiation times), and avoidance of potential side-effects if oral PUVA is used. If NB-UVB were equivalent or superior to PUVA there would be a strong case to use it as a first-line treatment. We report the first randomized observer-blinded pilot study to compare NB-UVB with immersion PUVA using validated outcome measurements.
Patients and methods
The trial was conducted as a single-centre, observer-blinded, prospective, randomized pilot trial. The primary objective was to demonstrate the feasibility of recruiting, treating and retaining patients and obtaining accurate data defining the clinical response of HE to NB-UVB and immersion PUVA. Patients were recruited from clinics at Newcastle Dermatology at the Newcastle Hospitals NHS Trust. The department has 16 clinics per day and treats around 1000 patients per week. HE was diagnosed by history and examination and biopsies were not taken. The trial was registered with the International Standard Randomized Controlled Trials Number (ISRCTN) registry, number ISRCTN18213910.
Eligibility and exclusion criteria
Patient eligibility and exclusion criteria are shown in Table 1 . Eligibility included palmar HE only, to minimize the dosing complexity that would have resulted from the different doses required for the thinner skin on the dorsal surfaces. One of the main inclusion criteria was 'not responding to topical treatments', targeting patients who, after treatment by a dermatologist with standard topical treatments, had not improved and needed second-line treatments. In practice, this will have included nonresponse to superpotent topical steroids and often tacrolimus, although there were no defined rules regarding prior treatment choices. Patients with mild eczema elsewhere on the body were eligible, but those with more widespread eczema where palmar eczema was not the predominant problem were excluded from the study.
Randomization and treatment details
Patients were randomized on a 1 : 1 basis using a random block allocation method, stratified by sex and eczema severity using Physician's Global Assessment (PGA), severe vs. mild/ moderate. Randomization was performed centrally by a secure web-based system and the schedule produced by a statistician not involved with the trial. The flow of patients through the trial is shown in Figure 1 . Patients were randomized into two groups as follows: Group 1 (standard treatment) received immersion PUVA twice weekly. Patients' hands were immersed in psoralen solution (0Á5 mL of 8-methoxypsoralen 1Á2% in 2 L of tap water) for 15 min followed by exposure to UVA radiation at an initial dose of 0Á5 J cm À2 according to the British Photodermatology Group guidelines. 10 The doses were then increased for each treatment (1Á0, 1Á5, 2, 3, 4, 5, 6 J cm À2 ). The maximum dose was 6 J cm À2 and the maximum potential cumulative dose 125 J cm À2 (incremental doses over 3 weeks plus 18 treatments 9 6 J cm À2 ).
Group 2 (intervention treatment) received NB-UVB twice weekly. The initial dose was 0Á5 J cm À2 and was increased by 20% increments to a maximum of 10 J cm À2 . The maximum potential cumulative dose was 123 J cm À2 .
Phototherapy was delivered using Waldmann 181 units fitted with UVA or NB-UVB bulbs (Waldmann Lichttechnik GmbH, Villingen-Schwenningen, Germany). The devices were calibrated and maintained throughout the trial by the medical physics department at Newcastle Hospitals NHS Trust.
For both groups, doses were reduced if erythema developed. Once symptoms had settled patients were restarted at Table S1 (see Supporting Information). PUVA, psoralen-ultraviolet A; NB-UVB, narrowband ultraviolet B.
the last dose that had been tolerated without side-effects. Trial exit criteria for both groups were completing 12 weeks of treatment (24 separate treatments) or attaining 'clear' or 'almost clear' as defined by the PGA score. Patients were permitted to use unlimited emollients during the trial and had to stop using topical steroids for 48 h before trial commencement and their first dose of UV irradiation. To allow for missed appointments, but to avoid major disruption to dosing schedules, we allowed patients to complete their 12 weeks of treatment within a maximum 14-week time frame.
Outcome measures
The primary outcome measure was the proportion of patients achieving a PGA 'clear' or 'almost clear' treatment response at 12 weeks (or at their last visit if they achieved this before 12 weeks). The 'index hand' was defined as the worst-affected hand at baseline, or if both hands were the same at baseline, the hand with the best response was analysed for the primary outcome. The PGA score is described by Ruzicka et al.
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Secondary outcome measures included: (i) the modified Total Lesion Severity Score (mTLSS), a score with seven components scored from 0 to 3 with a maximum of 21; (ii) the patient-reported Dermatology Life Quality Index (DLQI), a validated measure of the effect of skin disease on patients' daily activities; and (iii) safety measures.
The choice of outcome measures was influenced by those used in the largest randomized trial of HE investigating the efficacy and safety of alitretinoin. 11 In this trial, the PGA scoring was interpreted such that a patient could be classified as 'severe' by either symptoms or involved surface area criteria. A final outcome measure was feasibility, defined as the number of patients randomized as a proportion of the number of potential eligible participants.
Hand eczema severity assessments and blinding
At randomization, HE types, duration, presence at other sites, previous therapeutic interventions and pre-existing medical conditions were recorded. At randomization and at weeks 4, 8 and 12, patient HE severity (PGA and mTLSS) was independently assessed by one of two clinicians, who were blinded to the treatment modality being used. The attending nursing staff and patients receiving treatment were unblinded. The assessing clinicians were trained in utilizing the PGA and mTLSS using standardized photographs of HE severity and real patients to improve parity. 12 Patients were examined before their treatments in a closed office in an area of the department separate from the phototherapy equipment. At baseline and at each subsequent visit, DLQI was determined via patient questionnaire.
Sample size and statistical analysis plan
As this was a pilot study, the sample size was chosen as an achievable target based on the minimum conventional threshold for making parameter estimates in pilot studies, 13 aiming to recruit 60 patients with baseline and 12-week scores. Allowing for 20% potential dropouts and loss to follow-up inflated the recruitment target to a total of 76 patients.
As this was a pilot study, the statistical analyses were focused on descriptive statistics reporting primarily feasibility and response rates on an intention-to-treat basis. Feasibility is calculated as the number of patients randomized as a proportion of the number of potential eligible participants. The primary outcome measure was the PGA response rate at 12 weeks, calculated as the number of 'clear' or 'almost clear' responders as a proportion of the number of patients randomized. Additional per protocol PGA response rates are reported as a planned sensitivity analysis. Longitudinal data, including PGA and mTLSS scores, are plotted over time. Patients with PGA response were assessed for duration of response. Patientreported quality of life was scored according to the DLQI and is reported descriptively over time. 14 
Adverse event documentation
Expected phototherapy-related side-effects include various grades of erythema. Adverse events were recorded and graded on a three-point severity scale of mild, moderate or severe, while causality for each event was assessed as unrelated, unlikely, possible, probable, definite or not assessable. Severity was defined as follows. Mild: discomfort noted with no disruption of activities of daily living (ADLs); moderate: discomfort sufficient to limit normal ADLs; severe: incapacitating discomfort with inability to work or perform ADLs. The number of patients experiencing at least one severe episode is reported as the percentage of the total number of patients receiving treatment and as the total number of patients randomized.
Results

Recruitment and randomization
From August 2012 to April 2014, 105 patients were assessed via dedicated trial recruitment clinics where the diagnosis and categorization of patients' HE was made by a consultant dermatologist. In total, 105 patients were screened; 73 patients fulfilled the eligibility criteria and 32 were excluded (Table S1 ; see Supporting Information). Thirteen eligible patients declined to enter, mainly (69%) due to inability to commit to twice-weekly visits, travel difficulties and issues with work commitments. Three of the 13 were not entered due to specifically requesting PUVA treatment. A total of 60 patients were consented and randomized: 38 (63%) were female and 25 (42%) had severe disease, approximately balanced across the randomized treatment groups through stratification. Feasibility, as assessed by recruitment rate, was 82Á2% [95% confidence interval (CI) 73Á4-91Á0]. The total number of patients randomized was lower than the target of 76 due to difficulties in recruiting and subsequent time and financial limitations.
Patient demographics
The predominant type of HE was hyperkeratotic (47%). The median duration of HE was 2Á5 years (range 0Á3-35), with 42% reporting eczema at body sites other than their hands (Table 2) . It is unusual for there to be no cases of contact eczema reported. Patch testing was not part of the protocol and no analysis has been done based on subtype. We reported the predominant HE type and it is possible that some patients may have had a contribution to their disease from contact allergy. In a full study it would be important to document contact allergy accurately with patch testing of all participants. None of the randomized patients had previously tried any systemic therapy for their HE.
Treatment received and adverse events
One patient randomized to PUVA decided not to participate in the study and did not start treatment. The median [interquartile range (IQR)] number of treatments was 24 (17-24) for the 29 PUVA patients and 22 (16) (17) (18) (19) (20) (21) (22) (23) (24) for the 30 NB-UVB patients (Table S2; In total 54 adverse events were reported in 29 (49%) patients (Table S3 ; see Supporting Information). Of these, 37 (PUVA n = 10, 19%; NB-UVB n = 27, 50%) were classed as mild (discomfort noted, no disruption to ADLs). In total 17 moderate or severe events were reported in 13 (22%) patients; 14 events in 10 patients were in the NB-UVB group (none was severe, eight were treatment related) and three events in three patients were in the PUVA group (one severe, none treatment related). Most of the NB-UVB adverse events were predictable due to erythema or burning. There was one reported serious adverse event in the NB-UVB arm due to abdominal pain requiring admission, which was judged to be unrelated to the trial treatment.
Primary outcome measure: Physician's Global Assessment
The PGA scores at baseline for the index hand were 11 (18%) mild, 24 (40%) moderate and 25 (42%) severe (Table 3 ). In Values are n (%) unless stated otherwise. PUVA, psoralen-ultraviolet A; NB-UVB, narrowband ultraviolet B; IQR, interquartile range. (Table 4) .
Secondary outcome measures
The secondary outcome measures were recorded at baseline, week 4, week 8 and the end of the study (week [12] [13] [14] . Median mTLSS scores decreased during the treatment period in both randomized groups (Fig. 2) , where decreased score indicates decreased severity. The sizes of reductions were similar in both groups: the respective median (IQR) mTLSS scores at randomization and end of study were 9Á5 (6Á8-12) and 3 (1-6) for PUVA, and 9 (6Á8-11) and 4 (2-8) for NB-UVB. There was a marked reduction in mTLSS scores for both treatments in patients who achieved the primary PGA response compared with those patients who did not ( Fig. S1 ; see Supporting Information).
There was a progressive reduction in DLQI in both groups over time, where reduced DLQI indicates improved quality of life (Fig. 3) . The size of the reductions was similar in both groups: the respective median (IQR) DLQI scores at randomization and the end of study were 9Á5 (7Á8-15Á5) and 2 (0-11) for PUVA, and 10Á5 (7-16) and 4 (2-7) for NB-UVB.
Only 19 patients (32%) were followed to the 26-week follow-up due to lack of patient availability, giving too small a dataset for meaningful analysis.
Discussion
We have conducted a pilot study investigating NB-UVB and immersion PUVA for the treatment of palmar HE resistant to topical therapy. Both treatment modalities were shown to be safe, with good patient acceptability. The higher rate of treatment-related adverse events in the NB-UVB group was not unexpected, as NB-UVB is more likely to cause erythema than is PUVA. The degree of erythema experienced by an individual patient is related not only to dose but also to epidermal thickness, UV penetration, local factors that influence photoadaptation, and biochemical factors influencing erythema. No patients withdrew from the study because of adverse events; however, further work on dosimetry may succeed in reducing the episodes of NB-UVB-mediated erythema.
Almost twice as many patients in the PUVA group (43%, 95% CI 26-61) achieved the primary outcome (clear or almost clear PGA) than in the NB-UVB group (23%, 95% CI 8-38), although there are wide overlapping CIs. A similar difference was not seen in the mTLSS and DLQI data. The mTLSS is a 21-point score and provides a more sensitive and detailed description of the HE severity. Patients with only small differences in the mTLSS can be allocated different PGA scores. The categorical nature of the PGA score may therefore amplify the differences between groups. We recommend that future studies use a scoring system with a continuous measurement as the primary outcome measure, rather than the categorical PGA. As with the mTLSS, the DLQI scores were similar between the two groups, suggesting that the largely PGA-determined primary outcome difference is possibly misleading. Due to the relatively small size of the study, firm conclusions cannot be made on response by HE subtype. However, the majority of patients had hyperkeratotic HE and their thickened epidermis may have influenced the penetration of the UV, with UVA penetrating more readily than UVB. Any future studies will need to balance the groups carefully for HE types.
The design of this trial was in part based on the alitretinoin study of Ruzicka et al. 11 In retrospect, a better primary outcome would have been a continuous scale such as the Hand Eczema Clinical Severity Index (HECSI). 15 Advantages of the HECSI include more accurate recording of the area involved and a lack of subjective measures such as itch, but the disadvantage is increased complexity and a longer scoring time.
Future studies could consider its use in addition to PGA, mTLSS and DLQI. For ethical reasons, there was no control group and it is therefore possible that some patient improvement may have been through regression to their mean severity values, where they were recruited at their most severe and through the natural fluctuation of inflammatory skin, the disease was better 12 weeks later at the end of the trial. However, clinical experience of patients with severe chronic HE suggests that without treatment most remain severely affected, and so most improvements seen in this study are likely to be a result of the interventions. One option would be to treat only one hand and monitor the untreated hand for any concomitant severity changes, although HE is often asymmetric in severity, which limits this study design.
The literature regarding phototherapy for HE is fragmented, consisting of small, nonrandomized studies, retrospective case series and inclusion of patients with noneczematous dermatoses. This makes it difficult to draw definite conclusions regarding best practice. Numerous small studies have demonstrated the benefits of PUVA for HE and are consistent with the wide clinical experience of this treatment. [16] [17] [18] There have been other comparisons of PUVA vs. UVB, but most of the studies were small and did not use validated scoring systems. Rosen et al. compared broadband UVB with oral PUVA in a randomized, nonblinded study that recruited 35 patients with various forms of HE (primarily allergic contact dermatitis). 18 Using a nonvalidated scoring method, they concluded that oral PUVA was superior to UVB treatment. However, it is unlikely that the sample size used was sufficient to make a statistically significant conclusion. In 1997, Simons et al. performed a right-left comparison of topical PUVA vs. NB-UVB in 13 patients with chronic HE and concluded that there was no statistical difference in efficacy, although the PUVA-treated hands had more episodes of burning. 17 In 2007, Sezer and Etikan performed a randomized, prospective right-left comparison study on 15 patients with chronic HE, treating them with either immersion PUVA or NB-UVB three times a week for 9 weeks, with similar results seen for both treatments. 9 Adhering to standard dosimetry schedules, the short-term safety profile of both therapies appears limited to episodes of erythema. However, the long-term safety of repeated treatment courses to the hands is yet to be elucidated for either immersion PUVA or NB-UVB. Further work is needed to investigate the optimal dosing regimen for NB-UVB in HE. While this study treated only the palms, the thinner dorsal surfaces may be more prone to erythema, and careful investigation will be needed to determine the starting doses and increments when using NB-UVB in this area.
Ultimately, a noninferiority study comparing PUVA against NB-UVB would help to determine the order of treatment choice. This would be challenging due to the patient numbers required to provide sufficient statistical power. The introduction of an effective licensed oral agent for HE, alitretinoin, may also lead to a reduced demand for phototherapy. The U.K. National Institute for Health Research is currently conducting the ALPHA study comparing PUVA vs. alitretinoin, and these results may also have a big impact on treatment choice and the current widespread use of phototherapy for HE. 19 For these reasons, the need for a definitive noninferiority trial of NB-UVB vs. immersion PUVA will be reviewed following the results of ALPHA.
This randomized pilot trial has confirmed feasible levels of randomization and retention, acceptable treatment schedules demonstrating high compliance, and acceptable safety profiles for each arm. It has quantified the variation in disease. This trial has shown that while NB-UVB did result in more frequent episodes of erythema, overall it was safe and well tolerated and did produce improvements for some patients. Immersion PUVA was well tolerated. NB-UVB is proposed as a safe treatment option for patients desiring a shorter hospital visit for their treatment or when PUVA has not been effective. Further investigation is needed to determine whether one treatment is superior to the other.
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